Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.33 |
| ▸ | KDR | P35968 | 6/20 | 0.33 |
| ▸ | FLT3 | P36888 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25306906 | 0.93 | FGFR3 (0.34) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL25842025 | 0.88 | HPGD (0.33) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL30492483 | 0.87 | — | — | |
| SCHEMBL25306418 | 0.87 | — | — | |
| SCHEMBL25261754 | 0.82 | HRH4 (0.31) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL30492557 | 0.82 | HRH4 (0.31) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL25256867 | 0.79 | FGFR2 (0.37) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL25300105 | 0.76 | ALK (0.39) | — | |
| SCHEMBL25201045 | 0.75 | F2RL3 (0.31) | — | |
| SCHEMBL25303658 | 0.75 | HRH4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023133225-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133225-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | FGFR1 4821/4885FGFR2 4766/4885FGFR4 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.